Osteoporosis drug found to be effective against oral cancer
Osteoporosis drug found to be effective against oral cancer
In a recent study conducted at Ohio State University in the United States, the scientists found osteoporosis drug to be effective against the oral cancer.
Scientists have conducted several tests on the mice, and these results showed osteoporosis drug (zoledronic acid) working well in controlling the oral cancer in the mice.
This study brings a new ray of hope in the head and neck cancer patients, as this could turn out to be a supplemental therapy for them in additional to the available treatments.
This drug, zoledronic acid is currently approved by FDA for the treatment of osteoporosis. Zoledronic acid (brand name – Zometa) stops bone resorption in osteoporosis patients by killing a bone damaging cell.
Scientists feel this drug has the potential to become an additional treatment option beyond the standard treatments like chemotherapy. Zoledronic acid is also considered to be a safe drug, and its ability to kill the bone resorption could benefit the oral cancer patients a lot.
As a part of the research, the scientists at Ohio State University tested zoledronic acid on mice dividing them into few groups. When compared, mice which were treated with zoledronic acid showed better results than the ones which were on a placebo treatment.


Comments
Post a Comment